262P Pragmatic clinical trial assessing response to neoadjuvant taxotere and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA): First report from the Nigerian breast cancer study group

Atara Ntekim ,Olalekan Olasehinde ,Mustapha Akanji Ajani ,Abiodun Popoola ,Onyinye Balogun ,Anthonia Sowunmi ,A Komolafe,A.i Sanni ,Theodore Karrison ,Adeleye Dorcas Omisore ,Adebola Daramola ,Christopher O Olopade ,T Olajide,F O Omodele ,F B Abdulkareem ,Adenike Temitayo Adeniji-Sofoluwe ,John Oladapo Obafunwa ,Ayorinde Folasire ,Abiola Ibraheem ,Olufunmilayo I Olopade

doi:10.1016/j.annonc.2023.09.459

262P Pragmatic clinical trial assessing response to neoadjuvant taxotere and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA): First report from the Nigerian breast cancer study group

Atara Ntekim , Olalekan Olasehinde + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.459

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: University of Ibadan, Obafemi Awolowo University, Lagos State University Teaching Hospital, New York Hospital Queens, Cornell University, NewYork–Presbyterian Hospital, Presbyterian Hospital, Lagos University Teaching Hospital, University of Chicago, University of Lagos, University of Illinois at Chicago

#HER2-positive Breast Cancer #Nigerian Women + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

262P Pragmatic clinical trial assessing response to neoadjuvant taxotere and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA): First report from the Nigerian breast cancer study group

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.